A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV-1 Who Have Maintained an Adequate Response to ART
Latest Information Update: 02 Aug 2022
Price :
$35 *
At a glance
- Drugs Vacc-4x (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Bionor Holding; Bionor Pharma
- 29 Jan 2018 According to a Bionor media release, Bionor Pharma changed its name to Bionor Holding.
- 13 Jun 2016 According to Bionor Pharma media release, Bionor had a collaboration with SCHARP since 2014 with the purpose of performing a post-hoc statistical analysis of data from this trial.
- 13 Jun 2016 Results published in Bionor Pharma media release.